Table 3.
Characteristics of SARS-CoV-2 delta VOC hospitalized patients.
| No Prior Infection (Reference) | 1 Dose Vaccinated | Primary Vaccinated | Booster Vaccinated | |
|---|---|---|---|---|
| n = 5064 | n = 339 | n = 4993 | n = 724 | |
| Average age (years) | 76.67 ± 8.02 | 77.44 ± 7.76 | 76.67 ± 7.39 | 78.6 ± 7.62 ** # |
| Female n (%) | 3214 (63.47) | 218 (64.31) | 2609 (52.25) ** | 348 (48.07) ** # |
| Comorbidities n (%) | ||||
| Heart failure | 338 (6.67) | 33 (9.73) * | 491 (9.83) ** | 85 (11.74) ** |
| COPD | 405 (8) | 28 (8.26) | 537 (10.76) ** | 91 (12.57) ** |
| T2DM | 1372 (27.09) | 116 (34.22) ** | 1866 (37.37) ** | 286 (39.5) ** |
| Malignancy | 533 (10.53) | 53 (15.63) ** | 911 (18.25) ** | 170 (23.48) ** # |
| Number of comorbidities n (%) | ||||
| None a | 2984 (58.93) | 161 (47.49) | 2153 (43.12) | 271 (37.43) |
| 1 b | 1598 (31.56) | 135 (39.82) | 2043 (40.92) | 302 (41.71) |
| 2 b | 402 (7.94) | 34 (10.03) | 643 (12.88) | 124 (17.13) |
| 3 b | 71 (1.4) | 9 (2.65) | 140 (2.8) | 26 (3.59) |
| 4 b | 8 (0.16) | 0 (0) ** | 14 (0.28) ** | 1 (0.14) ** # |
COPD: Chronic obstructive pulmonary disease, T2DM: Type 2 diabetes mellitus. All data are given as n or average ± standard deviation if not otherwise stated. a None of the investigated comorbidities is present. b The number of investigated comorbidities is present. * p < 0.05 vs. unvaccinated; ** p < 0.01 vs. unvaccinated, # p < 0.05 vs. primary vaccinated.